AMEX · NBY
NovaBay Pharmaceuticals, Inc.
$1.47-$0.48 (-24.62%)
NovaBay Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.53% below the high.
Loading market information…
NASDAQ · VIVS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
VivoSim Labs, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.36% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
VivoSim Labs, Inc.’s next earnings report is currently expected on Nov 5, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow VivoSim Labs, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Feb 19, 2025 |
| -$0.19+92.46% vs estimate |
| $24.00K-45.45% vs estimate |
| Q2 2025 | Nov 8, 2024 | -$1.68+46.15% vs estimate | $30.00K-26.83% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.47-$0.48 (-24.62%)
NovaBay Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.53% below the high.
$3.99+$0.00 (0.0%)
Impact BioMedical Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.02% below the high.
$23.52$0.00 (0.0%)
Cyclerion Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.38% below the high.
$0.37-$0.02 (-5.95%)
Pasithea Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 82.06% below the high.
$9.00+$0.39 (+4.57%)
Polyrizon Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.53% below the high.
$4.15+$0.04 (+0.97%)
Quoin Pharmaceuticals, Ltd.’s quoted price sits in the lower half of its reported 52-week range, 82.34% below the high.
$1.89-$0.24 (-11.27%)
Alaunos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.0% below the high.
$0.33-$0.00 (-0.78%)
PharmaCyte Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.01% below the high.
